NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELAPAR is an orally disintegrating tablet formulation of selegiline hydrochloride, a monoamine oxidase inhibitor (MAOI) approved in 2006. It is indicated for Parkinson's disease as an adjunctive treatment to levodopa therapy. The drug works by inhibiting monoamine oxidase type B, thereby increasing dopamine levels in the brain.
$0.626MPart D
LOE ApproachingDeclining
This product is in late-stage decline with minimal Part D spending ($626K in 2023), indicating a contracted commercial team and limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELAPAR offers limited career growth prospects due to its LOE-approaching status and minimal current market presence ($626K spending, 110 Part D claims). Roles on this product involve managing decline, optimizing channel strategy, and transitioning to generic/post-LOE maintenance rather than growth or innovation work.
Brand ManagerProduct Manager
Worked on ZELAPAR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.